论文部分内容阅读
目的探索尿激酶纤溶酶原激活物(urokinase type plasminogen activator,u PA)在急性髓系白血病(acute myeloid leukemia,AML)患者血清中的表达及与预后的关系。方法采用酶联免疫吸附的方法检测45例初始治疗前AML患者及10例健康体检者血清u PA蛋白表达水平,分别对其中25例预后不良组、10例预后良好组、10例预后中等组患者及10例正常对照组血清u PA蛋白表达水平进行统计学分析比较。结果初始治疗前AML患者血清u PA蛋白表达水平明显高于正常对照组,差异具有统计学意义(P<0.05);预后不良组AML患者血清u PA蛋白表达水平明显高于预后良好组及预后中等组,差异具有统计学意义(P<0.05)。结论 u PA蛋白的表达与AML患者危险分层密切相关,监测AML患者血清u PA蛋白表达水平有助于早期判断AML患者的预后。
Objective To investigate the expression of urokinase type plasminogen activator (u PA) in serum of patients with acute myeloid leukemia (AML) and its relationship with prognosis. Methods The serum levels of uPA in 45 patients with AML before treatment and 10 healthy controls were detected by enzyme-linked immunosorbent assay. Twenty-five patients with poor prognosis, 10 with good prognosis and 10 with moderate prognosis And 10 normal control group serum u PA protein expression levels were compared statistically. Results The serum uPA protein level of AML patients before initial treatment was significantly higher than that of normal control group (P <0.05). The expression of uPA protein in AML patients with poor prognosis group was significantly higher than that of patients with good prognosis and moderate prognosis Group, the difference was statistically significant (P <0.05). Conclusion The expression of u PA protein is closely related to the risk stratification in patients with AML. Monitoring u PA protein expression in serum of patients with AML may help to judge the prognosis of AML patients in the early stage.